Medicare spending analysis for Infectious Disease providers
Infectious Disease accounts for $5.3B in Medicare payments across 56.7K providers.
The specialty's average markup of 2.8x is below the overall Medicare average of 3.77x.
This specialty has been identified by HHS OIG as having elevated fraud risk based on historical enforcement patterns.
AI-generated analysis based on Medicare payment data.
Providers in this specialty flagged by the ML v2 fraud detection model
| Year | Payments | Services | Providers | YoY Change |
|---|---|---|---|---|
| 2014 | $534.1M | 37.9M | 5.1K | — |
| 2015 | $543.0M | 38.4M | 5.2K | +1.7% |
| 2016 | $537.7M | 32.7M | 5.4K | -1.0% |
| 2017 | $538.5M | 37.7M | 5.6K | +0.2% |
| 2018 | $537.7M | 40.1M | 5.7K | -0.1% |
| 2019 | $538.9M | 42.3M | 5.8K | +0.2% |
| 2020 | $540.8M | 40.4M | 5.8K | +0.3% |
| 2021 | $544.9M | 45.8M | 5.9K | +0.8% |
| 2022 | $486.3M | 41.1M | 6.0K | -10.8% |
| 2023 | $485.9M | 39.0M | 6.1K | -0.1% |
| # | Provider | State | Payments | Services | Avg/Service |
|---|---|---|---|---|---|
| 1 | Robert Brennan | VA | $15.9M | 1.1M | $14.73 |
| 2 | Robert Zajac | TX | $3.1M | 60.4K | $52.12 |
| 3 | Bachir Younes | CA | $2.5M | 29.3K | $85.09 |
| 4 | Pardeep Kumari | FL | $2.4M | 204.1K | $11.63 |
| 5 | Jeffrey Lin | FL | $2.2M | 2.1M | $1.04 |
| 6 | Michael Vincent Tablang | FL | $2.0M | 716.9K | $2.82 |
| 7 | Mezgebe Berhe | TX | $1.4M | 111.2K | $12.60 |
| 8 | Shehzadi Nagra | TX | $1.4M | 878.1K | $1.55 |
| 9 | Madhavi Rayapudi | GA | $1.3M | 2.5M | $0.51 |
| 10 | Akhilesh Sharma | AZ | $1.2M | 62.3K | $19.06 |
| 11 | Herman Miller | CA | $1.1M | 10.8K | $103.33 |
| 12 | Cheryl Mcdonald | TX | $1.1M | 34.8K | $31.48 |
| 13 | Riad Dali Ahmad | MI | $1.1M | 732.9K | $1.47 |
| 14 | Haris Mirza | FL | $1.1M | 386.4K | $2.76 |
| 15 | Todd Price | TX | $1.1M | 43.4K | $24.23 |
| 16 | Wahab Brobbey | IL | $1.0M | 33.3K | $30.96 |
| 17 | Mohamed Erritouni | FL | $1.0M | 1.7M | $0.59 |
| 18 | Arash Alborzi | CA | $1.0M | 9.7K | $103.73 |
| 19 | Connie Park | CA | $979.6K | 15.8K | $62.01 |
| 20 | Vishnu Chundi | IL | $978.9K | 69.3K | $14.14 |
| 21 | Minghsun Liu | CA | $952.7K | 10.5K | $91.00 |
| 22 | David Hines | IL | $948.7K | 74.5K | $12.73 |
| 23 | Darlington Udeh | TX | $935.5K | 36.3K | $25.77 |
| 24 | Nilesh Patel | CA | $906.3K | 14.9K | $60.91 |
| 25 | Robert Husney | NY | $892.8K | 10.9K | $81.96 |
| Code | Description | Payments | Services | Avg/Service |
|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | $128.1M | 2.0M | $63.66 |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | $104.9M | 1.1M | $95.55 |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | $62.6M | 453.8K | $137.95 |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | $33.1M | 316.7K | $104.49 |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | $27.0M | 302.8K | $89.27 |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | $9.1M | 180.3K | $50.43 |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | $8.8M | 144.1K | $61.18 |
| 99291 | Critical care, first 30-74 minutes | $8.6M | 49.4K | $173.88 |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | $8.2M | 63.8K | $128.27 |
| J0875 | Injection, dalbavancin, 5 mg | $8.1M | 690.6K | $11.71 |
| J0897 | Injection, denosumab, 1 mg | $7.5M | 414.1K | $18.20 |
| J3380 | Injection, vedolizumab, 1 mg | $4.5M | 262.8K | $17.10 |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | $4.5M | 112.5K | $39.80 |
| J1556 | Injection, immune globulin (bivigam), 500 mg | $3.3M | 58.9K | $56.22 |
| J3245 | Injection, tildrakizumab, 1 mg | $3.3M | 30.0K | $108.62 |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | $3.2M | 26.7K | $121.34 |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | $3.1M | 86.8K | $35.55 |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | $2.9M | 33.7K | $85.08 |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | $2.9M | 47.5K | $60.16 |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | $2.4M | 62.4K | $38.36 |
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.